Emtricitabine Active Not Recruiting Phase 3 Trials for Human Immunodeficiency Virus (HIV) Infections / Chronic Hepatitis C Virus (HCV) Infection Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02660905HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
NCT02831764An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
NCT02831673An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
NCT01910402A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)
NCT01694420Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
NCT03048422Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
NCT02403674Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)